[MRTX] Mirati Therapeutics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 110.7 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 5.35 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart MRTX

Refresh chart

Strongest Trends Summary For MRTX

MRTX is in the medium-term up 79% in 3 months and up 85% above S&P in 3 months. In the long-term up 1159% in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Mirati Therapeutics, Inc., a biopharmaceutical company, is engaged in the development and commercialization of therapeutics for cancer and fungal diseases. Its lead product candidates include MGCD265, a multi-targeted kinase inhibitor that is in Phase I/II clinical trials for the treatment of solid tumors indications, including liver, renal cell, gastric, head and neck, prostate, pancreatic, bladder, breast, hepatocellular, ovarian, and non-small cell lung cancers; and MGCD516, a kinase inhibitor that is in advanced preclinical development stage for the treatment of patients with non-small cell lung cancer and solid tumors. The company also evaluates development opportunities for mocetinostat, a spectrum-selective histone deacetylase (HDAC) inhibitor for the treatment of patients with myelodysplastic syndrome and lymphoma. In addition, it develops MG96077, a beta-lactamase inhibitor; and MGCD290 for antifungal indications. The company has license, and research and development collaboration agreement with Taih

Fundamental Ratios
Shares Outstanding19.91 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV1.66 Price/Cash Per Share1.63
Price/Free Cash Flow-3.35 ROA-58.16% ROE-62.61% ROI
Current Ratio13.93 Quick Ratio Long Term Debt/Equity Debt Ratio0.08
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities48.61 M Cash From Operating Activities-31.12 M Gross Profit
Net Profit-9.78 M Operating Profit-11.99 M Total Assets72.18 M Total Current Assets71.19 M
Total Current Liabilities5.11 M Total Debt Total Liabilities5.13 M Total Revenue
Technical Data
High 52 week67.83 Low 52 week25.5 Last close67.67 Last change-0.24%
RSI57.28 Average true range3.15 Beta1.56 Volume82.99 K
Simple moving average 20 days7.04% Simple moving average 50 days37% Simple moving average 200 days42.85%
Performance Data
Performance Week8.88% Performance Month50.41% Performance Quart73.29% Performance Half17.48%
Performance Year157.79% Performance Year-to-date59.52% Volatility daily3.96% Volatility weekly8.85%
Volatility monthly18.13% Volatility yearly62.81% Relative Volume200.6% Average Volume616.18 K
New High New Low


2019-03-05 16:30:00 | Mirati Therapeutics To Present At Upcoming Healthcare Conferences

2019-02-28 16:15:00 | Mirati Therapeutics Reports Fourth Quarter Financial Results

2019-02-25 08:10:00 | Analysis: Positioning to Benefit within Biogen, Mirati Therapeutics, PLDT, Zebra Technologies, Domino's Pizza, and Solar Capital — Research Highlights Growth, Revenue, and Consolidated Results

2019-02-19 16:15:00 | Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors

2019-02-07 16:30:00 | Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day

2019-02-04 17:01:00 | Here's Why Mirati Therapeutics Jumped 55.8% in January

2019-01-31 07:55:00 | Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics

2019-01-30 11:41:52 | How Many Insiders Sold Mirati Therapeutics, Inc. NASDAQ:MRTX Shares?

2019-01-23 07:22:47 | The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoporosis Drug Study

2019-01-22 16:01:00 | Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

2019-01-17 08:06:55 | The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US

2019-01-16 20:45:00 | Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

2019-01-16 16:01:00 | Mirati Therapeutics Announces Proposed Public Offering Of Common Stock

2019-01-15 16:21:00 | Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor

2019-01-15 07:55:00 | Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics

2019-01-10 06:00:00 | Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause

2019-01-09 08:39:01 | Mirati Therapeutics MRTX Catches Eye: Stock Jumps 5.4%

2019-01-07 08:30:00 | Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab OPDIVO®

2019-01-02 16:30:00 | Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

2018-12-20 16:42:00 | Mirati Therapeutics Added To NASDAQ Biotechnology Index

2018-12-12 03:27:54 | Hedge Funds Are Buying Mirati Therapeutics, Inc. MRTX

2018-12-10 16:15:00 | Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors

2018-12-04 07:20:00 | Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar — Discovering Underlying Factors of Influence

2018-11-30 08:25:15 | The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings

2018-11-29 17:20:00 | Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug IND Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849

2018-11-26 11:33:36 | Mirati Therapeutics Stock Has Delivered Solid Growth in 2018

2018-11-20 16:30:00 | Mirati Therapeutics To Present At The 30th Annual Piper Jaffray Healthcare Conference

2018-11-09 08:35:00 | Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting

2018-11-09 08:30:00 | Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting

2018-11-08 16:32:00 | Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors

2018-11-07 09:00:00 | Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference

2018-11-06 18:52:57 | Mirati: 3Q Earnings Snapshot

2018-11-06 16:15:00 | Mirati Therapeutics Reports Third Quarter Financial Results

2018-11-05 16:15:00 | Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting

2018-10-30 09:00:00 | Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer

2018-10-25 08:50:00 | Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-10-22 16:49:00 | Mirati Shares Fall After Cancer Trial Progress Report

2018-10-22 16:45:23 | Biotech Dives After Lung Cancer Regimen With Bristol Disappoints

2018-10-22 16:26:23 | These Companies Are Dragging Biotech Stocks Into A Pit On Cancer Tests

2018-10-22 11:51:00 | Why Mirati Therapeutics Inc. Is Plunging Today

2018-10-22 10:37:00 | Mirati Therapeutics stock drops 19.5% after cancer trial results

2018-10-22 06:10:00 | Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial

2018-10-21 05:10:00 | Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress

2018-10-15 16:30:00 | Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology ESMO 2018 Congress And Conduct Investor Call

2018-10-09 09:41:00 | 3 Biotech Stocks With Major Incoming Catalysts

2018-10-08 17:29:09 | Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy

2018-09-14 11:15:31 | Mirati Therapeutics Inc NASDAQ:MRTX: Time For A Financial Health Check

2018-09-11 12:18:34 | Why Endocyte’s Stock Price Rose 11.4% Yesterday

2018-08-29 16:30:00 | Mirati Therapeutics To Participate In Oncology Panels At The 2018 Citi Biotech Conference

2018-08-24 07:11:11 | Should Invesco DWA SmallCap Momentum ETF DWAS Be on Your Investing Radar?